Allen Jacob
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allen Jacob has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Heath Douglas White
Division of Pulmonary, Critical Care, and Sleep Medicine, Baylor Scott & White Health, Temple, Texas
1 shared publication - Jaret K. Shook
Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA
1 shared publication Jaret Shook
Doctor of Pharmacy Student, Ohio Northern University Raabe College of Pharmacy, Ada, OH, USA
1 shared publicationSujith Puskoor
Department of Internal Medicine, Baylor Scott and White Medical Center – Round Rock, Round Rock, Texas
1 shared publication- Thomas E. Hutson
Texas Oncology
1 shared publication Thomas Hutson
Division of Genitourinary Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, Dallas, TX, USA
1 shared publication
Latest Publications
- 19 November 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 35 (2) , 202-203
Bowel perforation in morbid obesity secondary to COVID-19 infection
The pathophysiology of SARS-CoV-2 is unique in the different pathways the virus utilizes to induce severe systemic inflammation, leading to a higher potential for critical care requirements and a poorer prognosis. Although there are several risk factors for the development of severe infection, one associated with poorer outcome is obesity. In this report, we present a case of bowel perforation in an obese patient with severe COVID-19 infection.
- 19 November 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 35 (2) , 202-203
Bowel perforation in morbid obesity secondary to COVID-19 infection
The pathophysiology of SARS-CoV-2 is unique in the different pathways the virus utilizes to induce severe systemic inflammation, leading to a higher potential for critical care requirements and a poorer prognosis. Although there are several risk factors for the development of severe infection, one associated with poorer outcome is obesity. In this report, we present a case of bowel perforation in an obese patient with severe COVID-19 infection.
- 6 January 2021
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 21 (4) , 365-372
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma
Introduction: There are 400,000 new cases of Renal Cell Carcinoma (RCC) and 175,000 deaths worldwide every year. Currently available frontline therapies to treat RCC have less toxicity than previously employed therapeutic agents, but drug resistance is still a clinically significant problem. Drug resistance occurs through angiogenic escape by the activation of pathways that are independent of the VEGF targets of most first-line therapies. The lenvatinib/everolimus and lenvatinib/pembrolizumab are part of a new generation of combinations that can combat this method of resistance to extend both progression-free survival and overall survival in patients with metastatic RCC. Areas covered: This article discusses the evolution of current data on the efficacy and safety of these two combinations and future directions for their implementation in the treatment of advanced renal cell carcinoma. Expert opinion: Future research will focus on these combinations in contrast with other currently approved regimens. Once specific biomarkers that predict response to treatment are identified, the future of treatment of mRCC will involve specifically tailored therapies for a patient’s genotype. Therapies unique only to the patient undergoing treatment will increase both efficacy and safety of new treatments, and that is the truly exciting future that awaits this field.
- 6 January 2021
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 21 (4) , 365-372
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma
Introduction: There are 400,000 new cases of Renal Cell Carcinoma (RCC) and 175,000 deaths worldwide every year. Currently available frontline therapies to treat RCC have less toxicity than previously employed therapeutic agents, but drug resistance is still a clinically significant problem. Drug resistance occurs through angiogenic escape by the activation of pathways that are independent of the VEGF targets of most first-line therapies. The lenvatinib/everolimus and lenvatinib/pembrolizumab are part of a new generation of combinations that can combat this method of resistance to extend both progression-free survival and overall survival in patients with metastatic RCC. Areas covered: This article discusses the evolution of current data on the efficacy and safety of these two combinations and future directions for their implementation in the treatment of advanced renal cell carcinoma. Expert opinion: Future research will focus on these combinations in contrast with other currently approved regimens. Once specific biomarkers that predict response to treatment are identified, the future of treatment of mRCC will involve specifically tailored therapies for a patient’s genotype. Therapies unique only to the patient undergoing treatment will increase both efficacy and safety of new treatments, and that is the truly exciting future that awaits this field.
- 21 July 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (28) , 2147-2164
Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma
The VHL mutation–HIF upregulation–VEGF transcription sequence is the principal pathway in the development of renal cell carcinoma. Tyrosine kinase inhibitors target the VEGF receptors to inhibit fu...
- 21 July 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (28) , 2147-2164
Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma
The VHL mutation–HIF upregulation–VEGF transcription sequence is the principal pathway in the development of renal cell carcinoma. Tyrosine kinase inhibitors target the VEGF receptors to inhibit fu...